EE199 Cost-Effectiveness of Pembrolizumab for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Colombia
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.500
https://www.valueinhealthjournal.com/article/S1098-3015(23)00600-9/fulltext
Title :
EE199 Cost-Effectiveness of Pembrolizumab for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00600-9&doi=10.1016/j.jval.2023.03.500
First page :
Section Title :
Open access? :
No
Section Order :
11881